“We are developing a versatile immunotherapy platform with broad therapeutic potential. ”
Christophe Hubert, President CEO of LinKinVax
⦁ Inception in 2020: spin-off of the vaccine research institute
⦁ First focus on infectious diseases and vaccines with mostly public funding, based on the work of Pr. Yves Lévy and team
⦁ 2023: novel focus on the broad therapeutic and partnering potential of its innovative dendritic cell-targeting CD40 mAbs platform in immunotherapy, starting in oncology
“Bringing the right antigen to the right activated cell, our solution generates a wide range of novel Dendritic Cell-based immunotherapy candidates.”
Pr. Yves Lévy, Chief Medical & Scientific Officer, Founder
Stimulating innate immunity and broad antigen-specific adaptative (humoral and cellular) immune responses.
By targeting dendritic cells (DCs) via our anti-CD40- antigen-presenting mAbs, we provoke DC maturation and the presentation of the pathogenic antigen of interest to naive or memory B, T, Cytotoxic T cells that will conduct the immune response against the cells that present such antigen.
A unique network of public and private partners
LinKinVax operates within a stable network of leading scientific institutions, pharmaceutical companies, and university hospitals.
With a binding contract with the French National Institute of Health and Medical Research (Inserm) as institutional coordinator and the Vaccine Research Institute (VRI) as scientific leader, LinKinVax secured access to a unique patent portfolio; an international network of clinical facilities; and world leading industrial subcontractors.
LinKinVax operates within a stable network of leading scientific institutions, pharmaceutical companies and university hospitals.
With a binding contract with the French National Institute of Health and Medical Research (Inserm) as institutional coordinator and the Vaccine Research Institute (VRI) as scientific leader, LinKinVax secured access to a unique patent portfolio; an international network of clinical facilities; and world leading industrial subcontractors.
Dendritic cells Discovery by Ralph Steinman
Nobel Prize in Physiology or Medicine for the discovery of the dendritic cell and its role in adaptative immunity by Ralph Steinman, Bruce Beutler and Jules Hoffmann
Creation of the Vaccine Research Institute (VRI) on dendritic cell-targeting vaccines by Yves Lévy
Creation of biotech start-up LinKinVax by Yves Lévy, André-Jacques Auberton, and Rémy Gaston-Dreyfus
SARS-CoV-2, HIV and HPV linked cancer immunotherapies progressing in clinical trials
November 2023: Appointment of a new president CEO, Christophe Hubert